- Prevention of chemotherapy-related nausea & vomiting:
- Adults: IV 0.25mg over 30 seconds *1 started 30 minutes before chemotherapy OR PO 0.5mg given1 our before chemotherapy
-
- 1 month- 7 years: IV 20mcg/kg infused over 15 minutes *1
- Started 30 minutes before chemotherapy
- Max 1.5mg/dose
- 1 month- 7 years: IV 20mcg/kg infused over 15 minutes *1
- Prevention of postoperative nausea & vomiting:
- IV 0.075mg infused over 10 seconds
- Started immediately before anesthesia
Injection: 0.05mg/mL
- For pediatric administration, do not use pre-filled syringe to administer a dose other than 0.25 g
Selective 5HT3 antagonist
It binds to 5-HT3 receptors both in peripheral and central nervous system with primary effects in GI tract
- Headache
- Constipation
- QT prolongation (postop nausea/vomiting use)
- Hypersensitivity to components
- Coadministration with apomorphine
- Apomorphine
- Cisapride
- Dronedarone
- Levoketoconazole
- Pimozide
- Thioridazine
Drug Status
Availability | Prescription only |
Pregnancy | Category B; Use with caution |
Breastfeeding | Use with caution |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Aloxi | 0.2mg/5mL | Injection | 1's | Modi Mundipharma | Europa Healthcare |
Palaton | 0.25mg/5mL | Injection | 1’s | Emcure Pharma | Medcure Healthcare |
Palaton | 0.5mg | Orodisperible tablet | 10’s | Emcure Pharma | Medcure Healthcare |
Palohalt | 0.25mg/5mL | Injection | 1’s | MSN Labs | MSN Labs |
Themiset | 75mg/1.5mL | Injection | 1’s | Themis Medicare | Pharma Specialities |
Themiset | 0.25mg/5mL | Injection | 1’s | Themis Medicare | Pharma Specialities |